You are here: Home » PTI Stories » National » News
Business Standard

Japan's Daiichi completely exits Sun Pharma

Press Trust of India  |  New Delhi 

Japanese drug maker Daiichi Sankyo has sold its entire holding in Sun Pharmaceutical Industries for an estimated Rs 20,420 crore, which it received following the merger of Ranbaxy into the Indian pharma major.

In a statement today, Daiichi said: "The sale of Sun Pharma shares has been completed."

The company further said it has sold its entire holding of 21,49,69,058 shares in Sun Pharmaceutical. At the average share price of about Rs 950, the value of its shares would be Rs 20,420 crore.

Yesterday, Daiichi Sankyo Company Ltd had announced its decision to sell "the entire or part of its holdings of Sun Pharmaceutical shares..."

It further said: "Daiichi Sankyo will make an announcement concerning the effect of any gain or loss on the sale of Sun Pharma shares when results of operations for the fiscal year ending in March 2015 are announced."

On Monday, Daiichi Sankyo said its board had approved selling a part or entire 9 per cent holding in Sun Pharma.

Daiichi got around 9 per cent stake in Sun Pharma following the merger of Ranbaxy with the Indian pharma major.

"The board of directors of Daiichi Sankyo Company Ltd approved a resolution on April 20 to sell entire or part of its holding of Sun Pharmaceutical Industries Ltd shares," the Japanese firm said in a statement.

Last month, Sun Pharma had announced completion of merger of Ranbaxy with itself, almost a year after announcing the USD 4-billion deal.

As part of the deal, Ranbaxy shareholders were to receive 0.8 Sun Pharma shares for every Ranbaxy share they held.

Daiichi Sankyo, which had acquired a majority stake in Ranbaxy in 2008 for around Rs 22,000 crore, held 63.4 per cent in the Gurgaon-based firm at the time of the merger.

"From the perspective of the improvement of corporate value, Daiichi Sankyo has performed a review of the Sun Pharma shares and reached a conclusion to sell the shares entirely or partially," it said.

The merger with Ranbaxy has fortified Sun Pharma's position as the world's fifth largest specialty generic pharma firm and the top-ranking domestic one with a significant lead in the market share.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, April 21 2015. 12:22 IST